• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System

    5/28/26 9:04:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- A new survey from Progyny (NASDAQ:PGNY), a global leader in women's health and family building solutions, found that people navigating fertility, pregnancy, postpartum, and menopause care increasingly view personalized, human-led healthcare guidance as essential to managing stress and navigating a complex healthcare system.

    Among surveyed members, 71% said their healthcare journey added stress to their daily lives, with the top sources including the financial impact of healthcare and treatment, healthcare system complexity, and work/life balance challenges. Patients are not just managing healthcare decisions; they are also managing emotional stress, uncertainty, and mental well-being, all while juggling the everyday demands of work and life. In fact, 43% of respondents said that stress impacted their ability to perform effectively at work.

    As Mental Health Awareness Month brings increased attention to the connection between healthcare experiences and emotional well-being, Progyny conducted this survey to better understand the value of human support in an increasingly AI-driven and digital healthcare landscape. The findings showed that more than 70% of respondents said they wish every healthcare experience included knowledgeable and trusted human support, like Progyny Care Advocates® (PCAs). The survey comes at a time when research continues to show that individuals experiencing infertility report levels of anxiety and depression comparable to those facing other serious medical conditions, including cancer and heart disease.

    "This research reinforces the importance of human connection and shows that technology alone is not enough, especially during deeply personal and emotional healthcare journeys," said Dr. Janet Choi, Chief Medical Officer, Progyny. "Patients are looking for more than coverage and digital tools; they want empathy, advocacy, reassurance, and trusted guidance throughout the entire experience. While technology can improve access and efficiency, human support remains one of the most essential components of a cohesive care journey."

    Progyny's human-led, PCA model connects every member with a dedicated expert trained to proactively provide both clinical and emotional support throughout their healthcare journeys. PCAs help members navigate treatment options, understand benefits coverage, access educational resources, and communicate more effectively with providers, while also serving as a trusted bridge between patients and the complex healthcare system. For many members, PCA support becomes an important source of reassurance during some of the most emotional moments of their care experience.

    "My PCA became a trusted source of support who truly knew me, my history, and my journey. When I learned my IUI cycle had not been successful, my PCA immediately called to check in on me, listen, offer encouragement, share mental health resources available to me, and discuss options for treatment next steps to help me navigate what can feel like a marathon of a fertility journey. I felt like I was talking to not only an expert, but also a friend. I'm incredibly thankful for her and for Progyny. It takes a very special person to do this work," said one Progyny member.

    Additional findings from the survey include:

    • 60% of respondents said their interactions with a PCA helped reduce stress related to the care they were seeking
    • Among those respondents, more than 75% said the support Progyny's PCA team provided significantly helped reduce stress
    • 63% said their PCA helped them feel more educated and empowered in their healthcare journey
    • 54% said their PCA helped them better communicate and self-advocate with providers

    Survey respondents included Progyny members navigating fertility, pregnancy and postpartum, and menopause and midlife healthcare journeys.

    To learn more about Progyny, visit Progyny.com.

    About Progyny

    Progyny is a global leader in women's health and family building solutions, trusted by leading employers, health plans, and benefit purchasers worldwide. Through its comprehensive and personalized approach, Progyny supports members across fertility and family building, pregnancy and postpartum, menopause and midlife, and parent and child well-being journeys. Progyny combines differentiated clinical care, integrated pharmacy support through Progyny Rx®, and personalized guidance from Progyny Care Advocates® to deliver improved member experiences and better health outcomes. For more information, visit www.progyny.com.

    For Further Information, Please Contact:

    Media:

    Alexis Ford

    media@progyny.com

    Investors:

    James Hart

    investors@progyny.com



    Primary Logo

    Get the next $PGNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    5/19/2026$30.00Hold → Buy
    Canaccord Genuity
    1/20/2026$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    1/8/2026$34.00Hold → Buy
    Truist
    12/9/2025$29.00Overweight
    Barclays
    11/12/2025$30.00Sector Weight → Overweight
    KeyBanc Capital Markets
    7/8/2025$28.00Market Perform → Outperform
    Leerink Partners
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    More analyst ratings

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Anevski Peter bought $1,930,896 worth of shares (79,500 units at $24.29), increasing direct ownership by 13% to 680,251 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    11/17/25 8:22:02 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    12/26/24 5:35:03 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    12/26/24 5:31:32 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System

    NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- A new survey from Progyny (NASDAQ:PGNY), a global leader in women's health and family building solutions, found that people navigating fertility, pregnancy, postpartum, and menopause care increasingly view personalized, human-led healthcare guidance as essential to managing stress and navigating a complex healthcare system. Among surveyed members, 71% said their healthcare journey added stress to their daily lives, with the top sources including the financial impact of healthcare and treatment, healthcare system complexity, and work/life balance challenges. Patients are not just managing healthcare decisions; they are also managing emotional stre

    5/28/26 9:04:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Share Repurchase Program

    NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program will be funded through available cash balances. Shares may be repurchased through open market repurchases, including through plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, depending on stock price, market conditions and other factors deemed relevant in the Company's sole discretion. The program may be suspended or discontinued at any time. There can be no assurances

    5/26/26 8:00:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference

    NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time. A live audiocast and replay will be available from the Events and Presentations section of Progyny's website at http://investors.progyny.com. About Progyny Progyny (NASDAQ:PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leadin

    5/11/26 10:57:11 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Progyny upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Progyny from Hold to Buy and set a new price target of $30.00

    5/19/26 8:28:11 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Progyny from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    1/20/26 8:45:21 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny upgraded by Truist with a new price target

    Truist upgraded Progyny from Hold to Buy and set a new price target of $34.00

    1/8/26 9:26:52 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    SEC Filings

    View All

    SEC Form 144 filed by Progyny Inc.

    144 - Progyny, Inc. (0001551306) (Subject)

    5/27/26 11:25:45 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Progyny, Inc. (0001551306) (Filer)

    5/27/26 9:13:46 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Inc. filed SEC Form 8-K: Other Events

    8-K - Progyny, Inc. (0001551306) (Filer)

    5/26/26 9:15:09 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 158 shares and sold $7,310 worth of shares (279 units at $26.20) as part of a pre-agreed trading plan, decreasing direct ownership by 0.55% to 78,626 units (SEC Form 4) (withholding tax)

    4 - Progyny, Inc. (0001551306) (Issuer)

    6/3/26 4:54:05 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Director Scott Cheryl exercised 14,667 shares at a strike of $13.00, covered exercise/tax liability with 7,228 shares and sold $196,278 worth of shares (7,439 units at $26.39) (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    6/3/26 4:53:10 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Chief Product Officer Clapp Geoffrey sold $39,137 worth of shares (1,530 units at $25.58), exercised 12,909 shares at a strike of $20.91 and covered exercise/tax liability with 11,379 shares (SEC Form 4) (for tax liability)

    4 - Progyny, Inc. (0001551306) (Issuer)

    6/3/26 4:52:01 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Financials

    Live finance-specific insights

    View All

    Progyny, Inc. Announces First Quarter 2026 Results

    Reports Record First Quarter Revenue of $328.5 MillionEarly Selling Season Activity Reflects Robust Demand for Women's Health and Family Building SolutionsReturned Value to Shareholders Through Repurchase of 8.8 Million Shares to Date Since November NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2026 ("the first quarter of 2026"), as compared to the three-month period ended March 31, 2025 ("the first quarter of 2025" or "the prior year period"). "We're pleased with the strong start to the ye

    5/7/26 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An

    4/23/26 1:55:46 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Fourth Quarter 2025 Results

    Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three- and twelve-month periods ended December 31, 2025 ("the fourth quarter of 2025" and "the full year", resp

    2/26/26 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Leadership Updates

    Live Leadership Updates

    View All

    Progyny CEO Named World Economic Forum Champion for Women's Health

    NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that CEO Pete Anevski has been honored with the recognition as a Champion for Women's Health by the World Economic Forum (the Forum) and the Global Alliance for Women's Health (GAWH). The community of Champions is a distinguished group of global leaders who are playing a critical role in driving advocacy efforts, shaping policies, fostering innovation, and unlocking investments to advance women's health. The exclusive Champions community spans diverse sectors, industries, and geographies, and includes figures such as: Helen Clark, former

    10/7/25 9:30:50 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board

    NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. "As Pr

    5/14/25 9:05:48 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

    NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

    4/17/25 9:36:59 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    12/6/24 10:11:35 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    11/14/24 4:31:23 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Progyny Inc. (Amendment)

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    2/14/24 6:29:49 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care